Mark Breidenbach
Stock Analyst at Oppenheimer
(3.87)
# 522
Out of 4,479 analysts
52
Total ratings
33.96%
Success rate
16.29%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $2.16 | +501.85% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $4.93 | +244.83% | 4 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $24.85 | +282.29% | 5 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.09 | +2,193.58% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $1.08 | +825.93% | 5 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.70 | +1,611.84% | 4 | Jun 26, 2023 | |
| NRIX Nurix Therapeutics | Assumes: Outperform | $25 | $18.93 | +32.07% | 2 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $4 | $0.53 | +653.30% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.69 | +314.20% | 6 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.60 | +1,900.00% | 2 | Mar 10, 2023 | |
| SYRS Syros Pharmaceuticals | Maintains: Outperform | $15 → $13 | $5.00 | +160.00% | 3 | Mar 3, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $7.73 | +94.05% | 5 | Mar 1, 2023 | |
| SYBX Synlogic | Maintains: Outperform | $90 → $120 | $1.43 | +8,291.61% | 3 | Oct 18, 2022 | |
| ACHL Achilles Therapeutics | Initiates: Outperform | n/a | $0.83 | - | 1 | Apr 26, 2021 | |
| BLUE bluebird bio | Upgrades: Outperform | n/a | $0.92 | - | 2 | Dec 13, 2019 | |
| MBIO Mustang Bio | Initiates: Outperform | n/a | $0.56 | - | 1 | Dec 21, 2017 |
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $2.16
Upside: +501.85%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $4.93
Upside: +244.83%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $24.85
Upside: +282.29%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $1.09
Upside: +2,193.58%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $1.08
Upside: +825.93%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.70
Upside: +1,611.84%
Nurix Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $25
Current: $18.93
Upside: +32.07%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.53
Upside: +653.30%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.69
Upside: +314.20%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.60
Upside: +1,900.00%
Syros Pharmaceuticals
Mar 3, 2023
Maintains: Outperform
Price Target: $15 → $13
Current: $5.00
Upside: +160.00%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $7.73
Upside: +94.05%
Synlogic
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.43
Upside: +8,291.61%
Achilles Therapeutics
Apr 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.83
Upside: -
bluebird bio
Dec 13, 2019
Upgrades: Outperform
Price Target: n/a
Current: $0.92
Upside: -
Mustang Bio
Dec 21, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.56
Upside: -